Reblozyl

Bristol Myers says it needs another year to hit target for new drugs
Reuters
Thu, 10/26/23 - 10:40 am
Bristol Myers Squibb
Reblozyl
Sotyktu
Zeposia
Bristol Myers gets key FDA approval for bone marrow disease drug
BioPharma Dive
Wed, 08/30/23 - 09:54 am
Bristol Myers Squibb
FDA
Reblozyl
myelodysplastic syndromes
Bristol Myers data make case for earlier use of bone marrow disease drug
BioPharma Dive
Thu, 05/25/23 - 08:31 pm
Bristol Myers Squibb
Reblozyl
Epogen
myelodysplastic syndromes
clinical trials
FDA Accepts sBLA of BMS' Reblozyl
Targeted Oncology
Mon, 05/1/23 - 10:01 pm
Bristol Myers Squibb
Reblozyl
FDA
MDS
anemia
With positive trial results, Bristol Myers looks to widen use of blood disease drug
BioPharma Dive
Mon, 10/31/22 - 04:13 pm
Bristol Myers Squibb
Reblozyl
myelodysplastic syndrome
Bristol Myers pulls plug on Reblozyl program for rare blood disorder, months after missed PDUFA date
Endpoints
Mon, 06/6/22 - 11:45 pm
Bristol Myers Squibb
Reblozyl
beta thalassemia
Bristol Myers Squibb, Merck hit setback in bid to expand Reblozyl's anemia nod
Fierce Pharma
Fri, 03/25/22 - 10:33 am
Bristol Myers Squibb
Merck
Reblozyl
FDA
beta thalassemia
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
Fierce Pharma
Mon, 01/10/22 - 11:49 pm
JPMHC 2022
Bristol Myers Squibb
Revlimid
patent cliffs
Opdivo
Eliquis
Reblozyl
Breyanzi
Merck & Co justifies paying up for Acceleron
EP Vantage
Fri, 10/1/21 - 10:46 am
Merck
Accleron
M&A
sotatercept
Reblozyl
PAH
Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches
Fierce Pharma
Thu, 02/4/21 - 08:15 pm
Bristol-Myers Squibb
generics
Revlimid
Zeposia
Reblozyl
Onureg
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches
Fierce Pharma
Fri, 11/6/20 - 12:38 am
Celgene
Bristol-Myers Squibb
Zeposia
Reblozyl
Onureg
CHMP backs BMS’ first-in-class anemia drug Reblozyl
Pharmaforum
Mon, 05/4/20 - 10:34 am
Bristol-Myers Squibb
EMA
CHMP
Reblozyl
anemia
Celgene
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS
Pharmaceutical Business Review
Mon, 04/6/20 - 10:30 am
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
MDS
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
Tue, 03/24/20 - 10:30 am
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
A Big Month Ahead for the FDA and Bristol-Myers Squibb
Motley Fool
Sat, 02/22/20 - 11:39 pm
Bristol-Myers Squibb
Celgene
FDA
ozanimod
Opdivo
Reblozyl
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Pharmaceutical Business Review
Wed, 12/4/19 - 10:34 am
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
myelodysplastic syndromes
FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease
BioSpace
Sat, 11/9/19 - 12:13 pm
Celgene
Acceleron
Reblozyl
anemia
beta thalassemia